Form 4: PharmaCyte Biotech Director Grants Power of Attorney

PharmaCyte Biotech, Inc. director Michael M. Abecassis has executed a Power of Attorney, authorizing legal representatives to manage Section 16 filings.

Summary

• Michael M. Abecassis, a director of PharmaCyte Biotech, Inc., has granted a Power of Attorney to specific individuals, including Joshua Silverman from the company and legal professionals from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
• This authorization allows the appointed attorneys-in-fact to execute and file Forms 3, 4, and 5, which are required under Section 16 of the Securities Exchange Act of 1934 for reporting beneficial ownership of securities.
• The Power of Attorney also grants broad authority to take any action deemed beneficial, in the best interest of, or legally required for the undersigned regarding these filings.
• The document specifies that the attorneys-in-fact are not assuming Mr. Abecassis's personal responsibility for Section 16 compliance.
• The Power of Attorney remains in effect until Mr. Abecassis is no longer required to file these forms, unless revoked in writing.
• A related Form 4 filing indicates that Michael M. Abecassis holds a stock option to buy 119,170 shares at $0.67, with a vesting date tied to the issuer's next annual meeting of stockholders, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it primarily addresses procedural compliance and standard compensation practices rather than significant operational or financial developments.

Positives

• Ensures timely and accurate compliance with SEC reporting requirements for beneficial ownership changes.
• Provides a clear delegation of authority for managing Section 16 filings, reducing potential administrative burdens on the director.
• The stock option grant suggests an alignment of the director's interests with those of the company and its shareholders, with potential upside if the stock price increases.

Negatives

• The need for a Power of Attorney for routine filings might indicate a busy schedule or potential logistical challenges for the director.
• The stock option's exercise price of $0.67 implies that the company's stock price would need to significantly increase for these options to be in-the-money and profitable.

Risks

• Potential for errors in filings if the appointed attorneys-in-fact are not fully briefed or if there are misinterpretations of the filing requirements.
• The vesting of options is contingent on continued service, meaning any departure from the company before the next annual meeting would result in forfeiture of these options.

Future Outlook

The Power of Attorney remains in effect until Mr. Abecassis is no longer required to file Forms 3, 4, and 5, or until it is revoked. The stock options are subject to vesting on the date of the Issuer's next annual meeting of stockholders, contingent on Mr. Abecassis's continued service.

Management Comments

• "The undersigned hereby grants to each such attorney-in-fact full power and authority to act separately and to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present..."
• "The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigneds responsibilities to comply with Section 16 of the Exchange Act."
• "The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis."

Industry Context

StockSavvy.ai notes that the execution of Powers of Attorney for SEC filings is a common practice for corporate insiders, particularly directors and officers, to ensure compliance with regulatory obligations, especially when managing multiple reporting requirements or during periods of significant corporate activity.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing ensures transparency in beneficial ownership, which is crucial for shareholder confidence. The stock option grant, if exercised, could lead to dilution but also aligns director incentives with stock performance.
• Management and Employees: The stock option grant serves as an incentive for the director, potentially reflecting broader compensation strategies within the company.
• Regulatory Bodies: The filing ensures compliance with SEC regulations, maintaining the integrity of public company disclosures.

Next Steps

• The attorneys-in-fact will manage and file any required Forms 3, 4, and 5 on behalf of Michael M. Abecassis.
• Michael M. Abecassis's stock options will vest on the date of PharmaCyte Biotech, Inc.'s next annual meeting of stockholders, provided he remains in service.

Key Dates

Keywords

Power of Attorney, SEC Filing, Section 16, Form 4, Beneficial Ownership, PharmaCyte Biotech, PMCB, Stock Options, Director, Compliance